PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) (FSE:18H) has announced that the current stage of the research of its disulfide linker technology in engineering analgesic peptides derived from endogenous pharmacology program is soon to complete, with the results currently being compiled and analyzed.
The Analgesic Program started in July 2018 in order to expand the use of the University of Queensland's disulfide linker technology to develop analgesic peptide-based therapeutics for moderate to severe pain and inflammation for possible commercialization, the company noted.
READ: PreveCeutical advances Dual Gene Therapy Research Program combatting Type 2 diabetes and obesity
PreveCeutical said it will provide results of the Analgesic Program when it has fully analyzed them.
In a statement, PreveCeutical's chair and chief executive officer, Stephen Van Deventer commented: "We are very pleased with the progress of our research and development programs, including the expected completion of the Analgesic Program, which is the third program that we have with UniQuest Pty Limited.
“We believe that potential pain therapies from this Analgesic Program will be very important in addressing the current global opioid crises."
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
The company's current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).